Call for more investment in cost-effective tuberculosis care.
作者信息
Fuady Ahmad
机构信息
Department of Community Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
Department of Public Health, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands.
出版信息
Lancet Reg Health West Pac. 2021 May 13;11:100157. doi: 10.1016/j.lanwpc.2021.100157. eCollection 2021 Jun.
Abstract
摘要
相似文献
1
Call for more investment in cost-effective tuberculosis care.
Lancet Reg Health West Pac. 2021 May 13;11:100157. doi: 10.1016/j.lanwpc.2021.100157. eCollection 2021 Jun.
2
Comparing research investment to United Kingdom institutions and published outputs for tuberculosis, HIV and malaria: a systematic analysis across 1997-2013.
Health Res Policy Syst. 2015 Nov 4;13:63. doi: 10.1186/s12961-015-0052-5.
3
Domestic returns from investment in the control of tuberculosis in other countries.
N Engl J Med. 2005 Sep 8;353(10):1008-20. doi: 10.1056/NEJMsa043194.
4
Cost-effectiveness of tuberculosis control strategies among immigrants and refugees.
Eur Respir J. 2005 Jun;25(6):1107-16. doi: 10.1183/09031936.05.00074004.
5
Strengthening health systems to improve the value of tuberculosis diagnostics in South Africa: A cost and cost-effectiveness analysis.
PLoS One. 2021 May 14;16(5):e0251547. doi: 10.1371/journal.pone.0251547. eCollection 2021.
6
Modeling the patient and health system impacts of alternative xpert® MTB/RIF algorithms for the diagnosis of pulmonary tuberculosis in Addis Ababa, Ethiopia.
BMC Infect Dis. 2017 May 2;17(1):318. doi: 10.1186/s12879-017-2417-6.
7
Mapping pneumonia research: A systematic analysis of UK investments and published outputs 1997-2013.
EBioMedicine. 2015 Jul 4;2(9):1193-9. doi: 10.1016/j.ebiom.2015.06.024. eCollection 2015 Sep.
8
Communicating Value in Simulation: Cost Benefit Analysis and Return on Investment.
Acad Emerg Med. 2017 Oct 26. doi: 10.1111/acem.13336.
9
Strengthening resistance testing for tuberculosis in India - Investment cost, throughput, and efficiency of new laboratories.
Tuberculosis (Edinb). 2022 Sep;136:102245. doi: 10.1016/j.tube.2022.102245. Epub 2022 Aug 6.
10
Cost-effectiveness of novel vaccines for tuberculosis control: a decision analysis study.
BMC Public Health. 2011 Jan 26;11:55. doi: 10.1186/1471-2458-11-55.
本文引用的文献
1
Tuberculosis in the Western Pacific Region: Estimating the burden of disease and return on investment 2020-2030 in four countries.
Lancet Reg Health West Pac. 2021 Apr 29;11:100147. doi: 10.1016/j.lanwpc.2021.100147. eCollection 2021 Jun.
2
COVID-19 and Tuberculosis-Related Catastrophic Costs.
Am J Trop Med Hyg. 2020 Dec 2;104(2):436-440. doi: 10.4269/ajtmh.20-1125.
3
Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study.
Lancet Glob Health. 2020 Sep;8(9):e1132-e1141. doi: 10.1016/S2214-109X(20)30288-6. Epub 2020 Jul 13.
4
Ending tuberculosis by 2030-Pipe dream or reality?
Int J Infect Dis. 2020 Mar;92S:S51-S54. doi: 10.1016/j.ijid.2020.02.021. Epub 2020 Feb 27.
5
Household contact investigation for the detection of tuberculosis in Vietnam: economic evaluation of a cluster-randomised trial.
Lancet Glob Health. 2019 Mar;7(3):e376-e384. doi: 10.1016/S2214-109X(18)30520-5.
6
Active case finding in tuberculosis-affected households: time to scale up.
Lancet Glob Health. 2019 Mar;7(3):e296-e298. doi: 10.1016/S2214-109X(19)30015-4.
7
Passive case finding for tuberculosis is not enough.
Int J Mycobacteriol. 2016 Dec;5(4):374-378. doi: 10.1016/j.ijmyco.2016.09.023. Epub 2016 Oct 28.
Zotero 插件